top of page

From Navy SEALs to CEOs: How Psychedelics are Revolutionizing Mental Health and Battling Stigma

Marcus Capone, a former Navy SEAL with distinguished combat honors, found himself in a battle he never expected: a struggle against post-traumatic stress disorder (PTSD) and anxiety. After years of ineffective treatment with conventional antidepressants and mood stabilizers, Capone turned to psychedelic-assisted therapy, a decision that transformed his life and highlights a groundbreaking yet controversial shift in mental health treatment.

Capone's journey is reflective of a broader issue affecting many individuals with treatment-resistant depression (TRD). Estimates from Johns Hopkins Medicine and the Cleveland Clinic indicate that about 30% of those with major depressive disorder do not respond to standard antidepressant medications. The traditional path for these patients involves a prolonged trial and error process with various medications, often exacerbating symptoms and increasing the risk of suicide.

In response to his own transformative experience, Capone co-founded TARA Mind in 2022, aiming to provide greater access to psychedelic-assisted therapy. TARA Mind connects patients with a network of therapists and clinics, offering IV ketamine treatments across 50 major metro areas and training programs for therapists. Capone advocates for employers to support these innovative treatments, emphasizing the significant economic burden of untreated mental illness, which costs the U.S. nearly $3.7 trillion annually.

The field of therapeutic psychedelics encompasses a variety of substances, including ketamine, LSD, MDMA (ecstasy), psilocybin (magic mushrooms), ibogaine, and DMT. Research suggests these drugs could offer effective treatments for a range of conditions, such as depression, PTSD, chronic pain, Alzheimer's, and substance abuse. Despite the promise, the exact mechanisms by which these drugs work are not fully understood, and their path to mainstream acceptance is fraught with challenges.

The use of psychedelics in therapy is not new. These substances have been part of cultural and healing practices for thousands of years, dating back to Mayan civilization around 1000 BCE. Today, as research and anecdotal evidence mount, there is a growing push to integrate these treatments into mainstream medicine. However, legal and regulatory barriers remain significant obstacles.

While most states now permit medical or recreational marijuana, psychedelics are still tightly regulated. Some states, like Colorado and Oregon, have loosened restrictions, increasing access to these therapies. The upcoming FDA decision on MDMA therapy for PTSD could be a pivotal moment for the field. However, concerns about data integrity from clinical trials pose additional hurdles for widespread acceptance.

Despite their potential, psychedelics come with notable health risks. High-frequency use can lead to addiction and severe conditions such as cannabis-associated psychosis, where individuals lose touch with reality. Additionally, interactions with other medications and the exacerbation of conditions like bipolar disorder are significant concerns.

Experts like Dr. David A. Gorelick of the University of Maryland emphasize the need for clinically supervised therapy to mitigate these risks. In such settings, patients receive comprehensive support before, during, and after psychedelic experiences, ensuring safety and maximizing therapeutic benefits.

The economic impact of untreated mental illness is staggering, and the potential cost savings from effective psychedelic treatments are significant. Employers are beginning to recognize the benefits of covering these therapies. For instance, Bon Secours Mercy Health covers nasal spray ketamine (Spravato) and is exploring other options. Boeing is also considering psychedelic drug coverage for its employees.

Investment in the psychedelic sector is booming, with a focus on drug development. Yet, experts argue that funding for care delivery is equally crucial. Lisa Evia of SeedFund Capital notes that while 96% of investment goes into drug development, effective care delivery systems are essential for the success of these therapies.

The future of psychedelic therapy hinges on continued research, regulatory advancements, and societal acceptance. As data from employer-covered treatments accumulate, insurance companies may become more likely to cover these therapies, further integrating them into mainstream healthcare.

Despite the challenges, the momentum behind psychedelic therapy is growing. Sherry Rais, CEO of Enthea, notes that the company has expanded its coverage from 500 to 150,000 lives within a year. The goal is to leverage this data to convince major insurers of the efficacy and cost-effectiveness of psychedelic treatments.

The journey of integrating psychedelics into mainstream mental health treatment is complex, marked by significant promise and substantial challenges. As research progresses and societal attitudes shift, these therapies could revolutionize the treatment of mental health conditions. However, careful consideration of health risks and regulatory hurdles is essential to ensure these treatments are both safe and effective.

Ask your question

  • Yes, the benefits for treatment-resistant conditions are wor

  • No, the health risks and regulatory challenges are too great

  • Unsure, more research and regulation are needed.


News (2).png
News (4).png
Check back soon
Once posts are published, you’ll see them here.
bottom of page